MHRA 150-day National Licencing Procedure Guidance – Updated MHRA 150-day National Licencing Procedure Guidance – Updated MHRA has updated the information relating to new actives substances and biosimilars... MHRA 150-day National Licencing Procedure Guidance – Updated
MHRA Guidance on the Vetting of Promotional Material for Medicines – Updated MHRA Guidance on the Vetting of Promotional Material for Medicines – Updated MHRA has updated their guidance on the vetting... MHRA Guidance on the Vetting of Promotional Material for Medicines – Updated
Windsor Framework Medicines Announcement Windsor Framework Medicines Announcement MHRA has announced that new measures as part of the Windsor Framework will commence on 1... Windsor Framework Medicines Announcement
MHRA Guidance on Centrally Authorised Products (CAPs) Bridging Mechanism MHRA Guidance on Centrally Authorised Products (CAPs) Bridging Mechanism MHRA has published guidance on Centrally Authorised Products (CAPs) Bridging Mechanism. MHRA Guidance on Centrally Authorised Products (CAPs) Bridging Mechanism
MHRA Publishes Marketing Authorisations Granted 15 May to 31 May 2023 MHRA Publishes Marketing Authorisations Granted 15 May to 31 May 2023 MHRA granted two OTC licences during 15-31 May 2023. MHRA Publishes Marketing Authorisations Granted 15 May to 31 May 2023
PAGB/AESGP EU Pharmaceutical Law Revision Webinar – Register Now! PAGB/AESGP Webinar – EU Pharmaceutical Law Revision As part of the EU pharmaceuticals strategy, and drawing lessons from the Covid-19... PAGB/AESGP EU Pharmaceutical Law Revision Webinar – Register Now!
CMDh Report from May 2023 Meeting CMDh Report from May 2023 Meeting The Co-ordination group for Mutual recognition and Decentralised procedures – human (CMDh) has published... CMDh Report from May 2023 Meeting
MHRA Updates Guidance on Submission of Nitrosamine Risk Evaluation, Risk Assessment and Confirmatory Testing MHRA Updates Guidance on Submission of Nitrosamine Risk Evaluation, Risk Assessment and Confirmatory Testing MHRA has updated its g... MHRA Updates Guidance on Submission of Nitrosamine Risk Evaluation, Risk Assessment and Confirmatory Testing
EMA/HMA Good Practice Guide for Industry on Prevention and Management of Shortages EMA/HMA Good Practice Guide for Industry on Prevention and Management of Shortages The European Medicines Agency (EMA) and... EMA/HMA Good Practice Guide for Industry on Prevention and Management of Shortages
MHRA Publishes Marketing Authorisations Granted 1 May to 14 May 2023 MHRA Publishes Marketing Authorisations Granted 1 May to 14 May MHRA granted one OTC licence during 1-14 May 2023. Details... MHRA Publishes Marketing Authorisations Granted 1 May to 14 May 2023
Medicines Legislation Adopted by the European Parliament in line with the Windsor Framework Medicines Legislation Adopted by the European Parliament in line with the Windsor Framework The European Parliament agreed... Medicines Legislation Adopted by the European Parliament in line with the Windsor Framework
Clinical Trials Information System (CTIS) Transparency Rules Clinical Trials Information System (CTIS) Transparency Rules A public consultation on the Clinical Trials Information System (CTIS) transparency rules has... Clinical Trials Information System (CTIS) Transparency Rules
